Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313599 · ClinicalTrials.gov registry record · Phase 1
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00313599 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 28 participants.
The verdict
NCT00313599, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may help paclitaxel work better by making tumor cells more sensitive to the drug. Lapatinib may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving lapatinib together with paclitaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib when given together with paclitaxel in treating patients with advanced solid tumors.
Interventions
- DRUG paclitaxel
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2006-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313599
The ClinicalTrials.gov registry entry for NCT00313599 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00313599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313599 about?
NCT00313599 is a clinical study titled "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may help paclitaxel work better by making tumor cells more sensitive to the drug. Lapatinib may also stop the ...
What is the current status of trial NCT00313599?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2006-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00313599?
The interventions under investigation include: paclitaxel (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00313599?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.